TELA Bio (TELA) Cost of Revenue (2018 - 2026)

TELA Bio has reported Cost of Revenue for 9 years, with the latest figure at $16.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue changed 0.43% year-over-year to $16.5 million; the trailing twelve-month figure through Mar 2026 stood at $25.5 million (down 50.96% YoY), and the FY2025 full-year result was $25.6 million, down 60.47% from the prior year.
• Cost of Revenue for Q1 2026 stood at $16.5 million, up from -$23.1 million in the prior quarter.
• The five-year high for Cost of Revenue was $47.0 million in Q4 2023, with the low at -$23.1 million in Q4 2025.
• Average Cost of Revenue over 5 years is $11.6 million, with a median of $14.5 million recorded in 2023.
• Year-over-year, Cost of Revenue surged 347.4% in 2024 and slumped 265.78% in 2025.
• Tracing TELA's Cost of Revenue over 5 years: stood at $11.6 million in 2022, then surged by 303.53% to $47.0 million in 2023, then tumbled by 70.3% to $14.0 million in 2024, then tumbled by 265.78% to -$23.1 million in 2025, then surged by 171.47% to $16.5 million in 2026.
• The last three Cost of Revenue figures came in at $16.5 million (Q1 2026), -$23.1 million (Q4 2025), and $15.2 million (Q3 2025), per Business Quant data.

Peer Comparison